Resolute Science

Resolute Science is a private, preclinical-stage biotech pioneering a new approach to treating solid tumors by targeting tumor-associated macrophages (TAMs) instead of cancer cells directly. Its Macrophage-Targeted Conjugates (MAC-TACs) platform aims to overcome common resistance mechanisms and treat aggressive, late-stage cancers. The lead program, RS-5, has demonstrated consistent anti-tumor efficacy and tolerability across extensive preclinical studies in multiple tumor models. The company is positioned to address a significant unmet need in oncology, particularly for patients who have exhausted conventional treatment options.

Macrophage-Targeted Conjugates (MAC-TACs): A platform of synthetic drug conjugates designed to be taken up by Tumor-Associated Macrophages (TAMs) in the tumor microenvironment. TAMs then process and deliver cytotoxic or radiotherapeutic payloads directly to neighboring cancer cells, bypassing common resistance mechanisms associated with direct tumor cell targeting.

The company operates in the competitive solid tumor therapeutics space, facing indirect competition from all approved and developmental oncology drugs. More directly, it competes with other companies developing therapies that target or modulate the tumor microenvironment and tumor-associated macrophages, though its specific 'trojan horse' payload delivery mechanism appears novel. Its success will depend on demonstrating superior efficacy or tolerability compared to other approaches.